The problem with developing drugs to target cellular processes has been that many cell types distributed throughout the body might all have the same ion channels. SK channels are also distributed throughout the brain, but it is becoming obvious that these channels might be made of more than one type of SK channel subunit. It is likely that different nerves have SK channels made from different subunits. This would mean that developing a drug to block a channel made of only one SK channel protein will not be therapeutically useful, but knowing that the channels are comprised of multiple SK subunits will be the key.
The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Liège in Belgium have discovered how to design drugs to target specific areas of the brain. The research will enable the design of more effective drug compounds to enhance nerve activity in specific nerves. The team has been working on a subtype of ion channel called SK channels. Ion channels are proteins that act as pores in a cell membrane and help control the excitability of nerves. Rather like an electrical circuit, ion channels work by allowing the flow of 'charged' potassium, sodium and calcium ions to enter or exit cell membranes through a network of pores formed by the channels, a subtype of which is the SK channel family. The researchers have been using a natural toxin found in bee venom, called apamin, known for its ability to block different types of SK channel.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
